Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2015-04-30 | Angus C. Russell has served as a director of our company since March 2015. ... The Audit Committee currently consists of Messrs. LaPenta, Jr., Collins, Russell, and Segal, each an independent director of our company under the NYSE MKT rules as well as under rules adopted by the SEC pursuant to the Sarbanes-Oxley Act of 2002. Mr. LaPenta, Jr. serves as the Chairman of the Audit Committee. ... The members of the Nominating and Corporate Governance Committee are Messrs. Thompson, Carroll, and LaPenta, Jr. Mr. Thompson serves as Chair. |
| 2016-04-28 | Angus C. Russell has served as a director of our company since March 2015. ... We believe Mr. Russell's extensive experience as a pharmaceutical industry executive and his experience as a director of other publicly traded pharmaceutical companies provides the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors. |
| 2017-04-25 | Angus C. Russell has served as a director of our company since March 2015. ... Mr. Russell holds an honorary Doctor of Business Administration from Coventry University, U.K. ... The following table and accompanying footnotes detail compensation paid to our directors for services rendered for the year ended December 31, 2016. Angus C. Russell $71,750 fees earned or paid in cash, $89,503 option awards, total $161,253. |
| 2018-04-27 | Angus C. Russell has served as a director of our company since March 2015. ... The Audit Committee currently consists of Messrs. LaPenta, Jr., Segal, Collins, and Russell. ... Angus C. Russell Fees Earned or Paid in Cash: $68,750, Option Awards: $165,115, Total: $233,865. |
| 2019-04-30 | Angus C. Russell has served as a director of our company since March 2015. ... Member of the Audit Committee. ... Director Compensation table shows $76,250 fees earned in cash and $180,039 option awards, total $256,289. |
| 2020-05-04 | Angus C. Russell has served as a director of our company since March 2015. ... Mr. Russell holds an honorary Doctor of Business Administration from Coventry University, U.K. |
| 2021-04-14 | Angus C. Russell has served as a director of our company since March 2015. Mr. Russell previously served as Chief Executive Officer of Shire PLC from June 2008 until April 2013. Mr. Russell served as the Chief Financial Officer of Shire from 1999 to 2008 and also served as Executive Vice President of global finance. Prior to joining Shire, Mr. Russell served at ICI, Zeneca and AstraZeneca PLC for 19 years, most recently in the role of Vice President, Corporate Finance at AstraZeneca. Mr. Russell also serves as a director of Mallinckrodt PLC [OTC: MNKKKQ], having served as the chairman of the board of Mallinckrodt since May 2018, Lineage Cell Therapeutics, Inc. [NYSE: LCTX] and Revance Therapeutics Inc. [NASDAQ: RVNC], where he serves as the chairman of the board. Mr. Russell previously served as a director of Shire PLC [NASDAQ: SHPG], Questcor Pharmaceuticals Inc. [NASDAQ: QCOR] and InterMune Inc. [NASDAQ: ITMN]. |
Data sourced from SEC filings. Last updated: 2025-06-17